Product
BGB-11417
Aliases
sonrotoclax, Sonrotoclax
5 clinical trials
12 indications
Indication
Mature B-cell MalignanciesIndication
Mature B-Cell MalignanciesIndication
LeukemiaIndication
lymphomaIndication
Small Lymphocytic LymphomaIndication
Chronic Lymphocytic LeukemiaIndication
Acute Myeloid LeukemiaIndication
Myelodysplastic SyndromesIndication
mantle cell lymphomaIndication
Mantle Cell LymphomaClinical trial
A Phase 1 Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of Bcl-2 Inhibitor BGB-11417 in Adult Patients With Mature B-cell MalignanciesStatus: Active (not recruiting), Estimated PCD: 2024-05-01
Clinical trial
A Phase 1a/1b Open-Label Dose Escalation and Expansion Study of Bcl-2 Inhibitor BGB-11417 in Patients With Mature B-Cell MalignanciesStatus: Recruiting, Estimated PCD: 2027-08-30
Clinical trial
A A Single-Arm, Open-Label, Multicenter Phase 2 Study to Evaluate the Efficacy and Safety of BCL2 Inhibitor BGB-11417 in Adult Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaStatus: Recruiting, Estimated PCD: 2024-11-30
Clinical trial
A Phase 1b/2, Open-Label, Dose Finding, and Expansion Study of the Bcl-2 Inhibitor BGB-11417 in Patients With Myeloid MalignanciesStatus: Recruiting, Estimated PCD: 2023-12-01
Clinical trial
A Single-Arm, Open-Label, Multicenter Phase 1/2 Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of BCL2 Inhibitor BGB-11417 in Patients With Relapsed or Refractory Mantle Cell LymphomaStatus: Recruiting, Estimated PCD: 2024-11-01